Omission of clinical target volume in radiotherapy for unresectable stage III non-small cell lung cancer: a propensity score matching analysis

In this cohort study of patients with unresectable stage III non-small cell lung carcinoma (NSCLC) undergoing radiation therapy, no statistically significant difference in survival was observed with omission of the CTV. However, omitting the CTV could reduce the incidence of grade ≥2 radiation pneumonitis, thereby alleviating the adverse reactions associated with this condition.